The 15-year study followed almost 150,000 post-menopausal women aged between 50 and 79. More than 3,100 women died of cancer over that time.
Those who reported taking the cholesterol-lowering drugs were less likely to have died of cancer than those who were not taking the drugs.
The findings showed lower death rates among those taking statins for several common cancers including breast, bowel and ovarian cancers.
But lung cancer death rates did not seem to be affected, contrary to previous research.
However, experts in UK cautioned that randomised trials were needed to confirm whether the findings were directly due to the drugs' effects.
The study was designed to take into account other factors that affect cancer risk, such as family history, age, BMI and smoking rates.
But Dr Richard Roope, Cancer Research UK's GP expert, said the research "doesn't prove that post-menopausal women should take statins to lower their risk of dying from cancer.
Dr Ange Wang of the Stanford University School of Medicine, who led the study, said her team was "very excited" by the results, but agreed that the study did not prove statins were the reason why people were less likely to die from cancer, and that more research was needed.
"I think it should be a priority given how common statins are and how much their use has expanded, and how prevalent cancer is," she said.
This idea was supported by the new findings, which found no differences in the rate women developed cancer among the different groups on the study - only between those who subsequently died of the disease.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories
Over 30 subscriber-only stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app